From a natural product lead to the identification of potent and selective benzofuran-3-yl-(indol-3-yl)maleimides as glycogen synthase kinase 3βinhibitors that suppress proliferation and survival of pancreatic cancer cells

Irina N. Gaisina, Franck Gallier, Andrei V. Ougolkov, Ki H. Kim, Toru Kurome, Songpo Guo, Denise Holzle, Doris N. Luchini, Sylvie Y. Blond, Daniel D. Billadeau, Alan P. Kozikowski

Research output: Contribution to journalArticle

Abstract

Recent studies have demonstrated that glycogen synthase kinase 3β (GSK-3β) is overexpressed in human colon and pancreatic carcinomas, contributing to cancer cell proliferation and survival. Here, we report the design, synthesis, and biological evaluation of benzofuran-3-yl-(indol-3-yl) maleimides, potent GSK-3β inhibitors. Some of these compounds show picomolar inhibitory activity toward GSK-3β and an enhanced selectivity against cyclin-dependent kinase 2 (CDK-2). Selected GSK-3β inhibitors were tested in the pancreatic cancer cell lines MiaPaCa-2, BXPC-3, and HupT3. We determined that some of these compounds, namely compounds 5, 6, 11, 20, and 26, demonstrate antiproliferative activity against some or all of the pancreatic cancer cells at low micromolar to nanomolar concentrations. We found that the treatment of pancreatic cancer cells with GSK-3β inhibitors 5 and 26 resulted in suppression of GSK-3β activity and a distinct decrease of the X-linked inhibitor of apoptosis (XIAP) expression, leading to significant apoptosis. The present data suggest a possible role for GSK-3β inhibitors in cancer therapy, in addition to their more prominent applications in CNS disorders.

Original languageEnglish (US)
Pages (from-to)1853-1863
Number of pages11
JournalJournal of Medicinal Chemistry
Volume52
Issue number7
DOIs
StatePublished - Apr 9 2009
Externally publishedYes

Fingerprint

Maleimides
Glycogen Synthase Kinase 3
Glycogen Synthase Kinases
Biological Products
Pancreatic Neoplasms
Survival
Cyclin-Dependent Kinase 2
Apoptosis
benzofuran
Neoplasms
Cell Survival
Colon
Cell Proliferation
Cell Line

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

From a natural product lead to the identification of potent and selective benzofuran-3-yl-(indol-3-yl)maleimides as glycogen synthase kinase 3βinhibitors that suppress proliferation and survival of pancreatic cancer cells. / Gaisina, Irina N.; Gallier, Franck; Ougolkov, Andrei V.; Kim, Ki H.; Kurome, Toru; Guo, Songpo; Holzle, Denise; Luchini, Doris N.; Blond, Sylvie Y.; Billadeau, Daniel D.; Kozikowski, Alan P.

In: Journal of Medicinal Chemistry, Vol. 52, No. 7, 09.04.2009, p. 1853-1863.

Research output: Contribution to journalArticle

Gaisina, Irina N. ; Gallier, Franck ; Ougolkov, Andrei V. ; Kim, Ki H. ; Kurome, Toru ; Guo, Songpo ; Holzle, Denise ; Luchini, Doris N. ; Blond, Sylvie Y. ; Billadeau, Daniel D. ; Kozikowski, Alan P. / From a natural product lead to the identification of potent and selective benzofuran-3-yl-(indol-3-yl)maleimides as glycogen synthase kinase 3βinhibitors that suppress proliferation and survival of pancreatic cancer cells. In: Journal of Medicinal Chemistry. 2009 ; Vol. 52, No. 7. pp. 1853-1863.
@article{0ac79af5c0224ffa88b2e562a8ecf10b,
title = "From a natural product lead to the identification of potent and selective benzofuran-3-yl-(indol-3-yl)maleimides as glycogen synthase kinase 3βinhibitors that suppress proliferation and survival of pancreatic cancer cells",
abstract = "Recent studies have demonstrated that glycogen synthase kinase 3β (GSK-3β) is overexpressed in human colon and pancreatic carcinomas, contributing to cancer cell proliferation and survival. Here, we report the design, synthesis, and biological evaluation of benzofuran-3-yl-(indol-3-yl) maleimides, potent GSK-3β inhibitors. Some of these compounds show picomolar inhibitory activity toward GSK-3β and an enhanced selectivity against cyclin-dependent kinase 2 (CDK-2). Selected GSK-3β inhibitors were tested in the pancreatic cancer cell lines MiaPaCa-2, BXPC-3, and HupT3. We determined that some of these compounds, namely compounds 5, 6, 11, 20, and 26, demonstrate antiproliferative activity against some or all of the pancreatic cancer cells at low micromolar to nanomolar concentrations. We found that the treatment of pancreatic cancer cells with GSK-3β inhibitors 5 and 26 resulted in suppression of GSK-3β activity and a distinct decrease of the X-linked inhibitor of apoptosis (XIAP) expression, leading to significant apoptosis. The present data suggest a possible role for GSK-3β inhibitors in cancer therapy, in addition to their more prominent applications in CNS disorders.",
author = "Gaisina, {Irina N.} and Franck Gallier and Ougolkov, {Andrei V.} and Kim, {Ki H.} and Toru Kurome and Songpo Guo and Denise Holzle and Luchini, {Doris N.} and Blond, {Sylvie Y.} and Billadeau, {Daniel D.} and Kozikowski, {Alan P.}",
year = "2009",
month = "4",
day = "9",
doi = "10.1021/jm801317h",
language = "English (US)",
volume = "52",
pages = "1853--1863",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "7",

}

TY - JOUR

T1 - From a natural product lead to the identification of potent and selective benzofuran-3-yl-(indol-3-yl)maleimides as glycogen synthase kinase 3βinhibitors that suppress proliferation and survival of pancreatic cancer cells

AU - Gaisina, Irina N.

AU - Gallier, Franck

AU - Ougolkov, Andrei V.

AU - Kim, Ki H.

AU - Kurome, Toru

AU - Guo, Songpo

AU - Holzle, Denise

AU - Luchini, Doris N.

AU - Blond, Sylvie Y.

AU - Billadeau, Daniel D.

AU - Kozikowski, Alan P.

PY - 2009/4/9

Y1 - 2009/4/9

N2 - Recent studies have demonstrated that glycogen synthase kinase 3β (GSK-3β) is overexpressed in human colon and pancreatic carcinomas, contributing to cancer cell proliferation and survival. Here, we report the design, synthesis, and biological evaluation of benzofuran-3-yl-(indol-3-yl) maleimides, potent GSK-3β inhibitors. Some of these compounds show picomolar inhibitory activity toward GSK-3β and an enhanced selectivity against cyclin-dependent kinase 2 (CDK-2). Selected GSK-3β inhibitors were tested in the pancreatic cancer cell lines MiaPaCa-2, BXPC-3, and HupT3. We determined that some of these compounds, namely compounds 5, 6, 11, 20, and 26, demonstrate antiproliferative activity against some or all of the pancreatic cancer cells at low micromolar to nanomolar concentrations. We found that the treatment of pancreatic cancer cells with GSK-3β inhibitors 5 and 26 resulted in suppression of GSK-3β activity and a distinct decrease of the X-linked inhibitor of apoptosis (XIAP) expression, leading to significant apoptosis. The present data suggest a possible role for GSK-3β inhibitors in cancer therapy, in addition to their more prominent applications in CNS disorders.

AB - Recent studies have demonstrated that glycogen synthase kinase 3β (GSK-3β) is overexpressed in human colon and pancreatic carcinomas, contributing to cancer cell proliferation and survival. Here, we report the design, synthesis, and biological evaluation of benzofuran-3-yl-(indol-3-yl) maleimides, potent GSK-3β inhibitors. Some of these compounds show picomolar inhibitory activity toward GSK-3β and an enhanced selectivity against cyclin-dependent kinase 2 (CDK-2). Selected GSK-3β inhibitors were tested in the pancreatic cancer cell lines MiaPaCa-2, BXPC-3, and HupT3. We determined that some of these compounds, namely compounds 5, 6, 11, 20, and 26, demonstrate antiproliferative activity against some or all of the pancreatic cancer cells at low micromolar to nanomolar concentrations. We found that the treatment of pancreatic cancer cells with GSK-3β inhibitors 5 and 26 resulted in suppression of GSK-3β activity and a distinct decrease of the X-linked inhibitor of apoptosis (XIAP) expression, leading to significant apoptosis. The present data suggest a possible role for GSK-3β inhibitors in cancer therapy, in addition to their more prominent applications in CNS disorders.

UR - http://www.scopus.com/inward/record.url?scp=64549112164&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=64549112164&partnerID=8YFLogxK

U2 - 10.1021/jm801317h

DO - 10.1021/jm801317h

M3 - Article

C2 - 19338355

AN - SCOPUS:64549112164

VL - 52

SP - 1853

EP - 1863

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 7

ER -